Search
Teclozan
go.drugbank.com/drugs/DB13205InvestigationalTeclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalIn November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Fluciclatide
go.drugbank.com/drugs/DB14842InvestigationalFluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.
TD-0903
go.drugbank.com/drugs/DB16463InvestigationalTD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants
Vabametkib
go.drugbank.com/drugs/DB21629InvestigationalVabametkib has a monoisotopic molecular weight of 566.3 Da.
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44156] Etranacogene dezaparvovec was approved by the FDA in November 2022 for the treatment of select patients with hemophilia B, becoming the first gene therapy approved for this indication.
Sulfaguanidine
go.drugbank.com/drugs/DB13726ExperimentalSulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.
Sinefungin
go.drugbank.com/drugs/DB01910ExperimentalThese are compounds comprising a purine base attached to a sugar.